


Understanding Coverage for AMVUTTRA[®] (vutrisiran)


AMVUTTRA is accessible and affordable for most patients, regardless of insurance type. While most patients receive AMVUTTRA through Medicare,¹ you can also access treatment through commercial insurance, which is individually purchased or provided through your employer.

MEDICARE



Medicare's **Medical** Benefit

- AMVUTTRA is usually covered under the medical benefit (Part B)
- Access to AMVUTTRA usually does not require prior authorization for Medicare Part B fee-for-service (FFS)
- Most patients with Medicare Part B FFS have supplemental coverage.^{2,3} Most of these patients treated with AMVUTTRA pay \$0 out of pocket (OOP)⁴



Medicare **Advantage**

- Many patients receive coverage for AMVUTTRA under Medicare Part C (Medicare Advantage)
- The average OOP cost for AMVUTTRA with Medicare Part C may vary

COMMERCIAL



- Commercial insurers provide coverage for some patients treated with AMVUTTRA
- Eligible patients with commercial insurance participating in the Alnylam Assist[®] Copay Program may pay \$0 copay for AMVUTTRA



Most patients treated with AMVUTTRA pay \$0 OOP⁴

Support Services Through Alnylam Assist[®]



Alnylam Assist[®] offers product support services throughout the treatment journey, including:

- Help understanding coverage and starting treatment
- Financial assistance programs^a that can help with the cost of medication, including copay support, a Patient Assistance Program, and programs that may help with coverage delays
- Patient Education Liaisons to provide one-on-one support to patients and their families with disease and treatment education

Learn more about Alnylam Assist[®]

To access helpful resources or learn more, visit
www.AlnylamAssist.com/amvuttra



8AM–6PM, Monday–Friday



1-833-256-2748



Scan to visit

www.AlnylamAssist.com

^aPatients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

References: 1. Chen et al. *J Am Heart Assoc.* 2022;11(7):e023895. 2. Statista. Accessed September 29, 2025. <https://www.statista.com/statistics/413074/medigap-enrollment-by-plan-type/> 3. Centers for Medicare & Medicaid Services. Accessed September 29, 2025. <https://www.medicare.gov/health-drug-plans/medigap/basics/compare-plan-benefits> 4. Data on file. Alnylam Pharmaceuticals, Inc.